Clinical Trials Browser

Recruiting × Triple Negative Breast Neoplasms × Epirubicin × Clear all

NCT06966700 2026-06-01

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Phase 3 Recruiting

2,400 enrolled

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05582499 2026-05-28

FASCINATE-N

Phase 2 Recruiting

716 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04771871 2026-05-07

TARMAC

Phase 2 Recruiting

42 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating, Triple Negative Breast Neoplasms

NCT06291064 2026-02-17

TARMAC

Phase 2 Recruiting

85 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Phase 2 Recruiting

51 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04138719 2025-09-11

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Phase 2 Recruiting

520 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05862064 2025-07-16

A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

Phase 3 Recruiting

606 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05447702 2023-05-22

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Phase 2 Recruiting

35 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04437160 2020-06-18

Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

Phase 2 Recruiting

286 enrolled

Breast

Triple Negative Breast Neoplasms